Grifols enters formal collaboration with the U.S. Biomedical Advanced Research Development Authority (BARDA) and FDA to collect plasma from convalescent Covid-19 patients.
- Will process plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat Covid-19
- In Spain, Grifols is working on a clinical test with inactivated plasma from recovered patients through a collaboration with donation centers, public hospitals
- Grifols comments in regulatory statement
To contact the reporter on this story:
To contact the editors responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with permission.